Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias

The NULISAseq pTau217 assay was comparable to the Simoa pTau217 assay, both utilizing the ALZpath antibody, in detecting amyloid positron emission tomography (PET) positivity, each with areas under the curve greater than 90%. Nineteen proteins were differentially expressed in participants with mild cognitive impairment (MCI) compared to those who were unimpaired. Markers of non-AD proteinopathies such as pTDP43-409, oligomeric alpha-synuclein, and huntingtin (HTT), were among those upregulated in MCI. High levels of plasma pTDP43-409 were associated with worsening hippocampal atrophy and cognitive decline, clinical indicators of limbic-predominant age-related TDP-43 encephalopathy (LATE), compared to those with low pTDP43-409.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2025-05-01
DOI
https://doi.org/10.1002/alz.70166
Citations
16
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
18.63

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias

Rachel Studer, Barbara B. Bendlin, Elizabeth M. Planalp, Erin M. Jonaitis et al.
16 citations
Alzheimer s & Dementia
Alzheimer's disease research and treatments
18.63
article

Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias

Rachel Studer, Barbara B. Bendlin, Elizabeth M. Planalp, Erin M. Jonaitis, Rachael E. Wilson, Julie Elisabeth Oomens, Nathaniel A. Chin, Henrik Zetterberg, Sterling C. Johnson, Ramiro Eduardo Rea Reyes, Sanjay Asthana, Rebecca E. Langhough
article en
16 citations

Abstract

The NULISAseq pTau217 assay was comparable to the Simoa pTau217 assay, both utilizing the ALZpath antibody, in detecting amyloid positron emission tomography (PET) positivity, each with areas under the curve greater than 90%. Nineteen proteins were differentially expressed in participants with mild cognitive impairment (MCI) compared to those who were unimpaired. Markers of non-AD proteinopathies such as pTDP43-409, oligomeric alpha-synuclein, and huntingtin (HTT), were among those upregulated in MCI. High levels of plasma pTDP43-409 were associated with worsening hippocampal atrophy and cognitive decline, clinical indicators of limbic-predominant age-related TDP-43 encephalopathy (LATE), compared to those with low pTDP43-409.

Alzheimer s & DementiaVol. 21(5)
University of Wisconsin–Madison (US), Sahlgrenska University Hospital (SE), UK Dementia Research Institute (GB), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), University of Gothenburg (SE)
Alzheimer's Association, National Institutes of Health
Openalex Percentile: Top 1%
Alzheimer's disease research and treatments
18.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.